A proven treatment option

15 Years

ENBREL treats five long-term inflammatory diseases: adult chronic moderate to severe plaque psoriasis in patients who are candidates for systemic therapy or phototherapy, moderate to severe rheumatoid arthritis (RA), moderately to severely active polyarticular juvenile idiopathic arthritis (JIA), psoriatic arthritis, and ankylosing spondylitis (AS).

ENBREL has played a role in helping many people with these conditions manage their disease.

Because ENBREL suppresses the immune system, patients are at a greater risk for getting serious infections. Please see full Prescribing Information, Important Safety Information, and Medication Guide for complete details about ENBREL.

ENBREL has an established safety profile

Doctor-prescribed for moderate to severe rheumatoid arthritis for over 15 years, ENBREL has an established safety profile. ENBREL has more than 20 years of RA clinical trials experience since its initial FDA approval for moderate to severe RA in 1998 and was the first medicine of its kind used to treat moderate to severe RA.

FDA Approvals:

  • 1998: FDA-approved for moderate to severe rheumatoid arthritis
  • 1999: FDA-approved for moderately to severely active polyarticular juvenile idiopathic arthritis
  • 2002: FDA-approved for psoriatic arthritis
  • 2003: FDA-approved for ankylosing spondylitis
  • 2004: FDA-approved for adult chronic moderate to severe plaque psoriasis in patients who are candidates for systemic therapy or phototherapy

The science of your symptoms

Chronic inflammatory diseases like moderate to severe rheumatoid arthritis, ankylosing spondylitis, and moderately to severely active juvenile idiopathic arthritis are believed to be caused by a problem with the immune system, which normally protects the body from infection and disease. An important protein involved in the immune response is called tumor necrosis factor (TNF). If you have one of these conditions, you may have too much active TNF in your body (among many changes in the immune system).

Although TNF is a normal part of the immune response, increased levels of TNF play a role in the inflammation associated with certain rheumatic conditions. ENBREL is not approved to treat all rheumatic conditions. See the approved indications for ENBREL below.

How ENBREL can help

ENBREL works on your immune system by reducing levels of the active form of TNF. In doing so, ENBREL can help to lessen inflammation and help you manage your symptoms.

Because ENBREL works on your immune system, it can lower the ability of your immune system to fight infections and may raise other safety concerns.

Please see full Prescribing Information, Important Safety Information, and Medication Guide for complete details about ENBREL.

Clinical experience and proven results

ENBREL can help reduce the pain, swelling, stiffness, and fatigue of your moderate to severe rheumatoid arthritis. It can also help keep joint damage from getting worse.

In clinical studies, ENBREL was shown to be effective in about 2 out of 3 adults with moderate to severe RA who used it. In moderate to severe RA, some patients treated with ENBREL in combination with methotrexate have had improvement in their symptoms in as little as 2 weeks. Most people who improved did so within 3 months, and among those who improved, some had additional improvement at 6 months. Your results may vary.

In an RA clinical study, 55% of patients who remained on ENBREL had no further progression of joint damage at 5 years.

Because ENBREL works on your immune system, it can lower the ability of your immune system to fight infections and may raise other safety concerns.

Please see full Prescribing Information, Important Safety Information, and Medication Guide for complete details about ENBREL.


We're here to help

We can answer any general questions you may have about ENBREL and help with more specific inquiries, including financial assistance, injection tips, and dosing information.

Prescription ENBREL is taken by injection.

Please scroll to read Important Safety Information and Indications.

IMPORTANT SAFETY INFORMATION AND INDICATIONS

What is the most important information I should know about Enbrel® (etanercept)?

ENBREL is a medicine that affects your immune system. ENBREL can lower the ability of your immune system to fight infections. Serious infections have happened in patients taking ENBREL. These infections include tuberculosis (TB) and infections caused by viruses, fungi, or bacteria that have spread throughout the body. Some patients have died from these infections. Your doctor should test you for TB before you take ENBREL and monitor you closely for TB before, during, and after ENBREL treatment, even if you have tested negative for TB.

There have been some cases of unusual cancers reported in children and teenage patients who started using tumor necrosis factor (TNF) blockers before 18 years of age. Also, for children, teenagers, and adults taking TNF blockers, including ENBREL, the chances of getting lymphoma or other cancers may increase. Patients with RA or psoriasis may be more likely to get lymphoma.

Before starting ENBREL, tell your doctor if you:

  • Have any existing medical conditions
  • Are taking any medicines, including herbals
  • Think you have, are being treated for, have signs of, or are prone to infection. You should not start taking ENBREL if you have any kind of infection, unless your doctor says it is okay
  • Have any open cuts or sores
  • Have diabetes, HIV, or a weak immune system
  • Have TB or have been in close contact with someone who has had TB
  • Were born in, lived in, or traveled to countries where there is more risk for getting TB. Ask your doctor if you are not sure
  • Live, have lived in, or traveled to certain parts of the country (such as, the Ohio and Mississippi River valleys, or the Southwest) where there is a greater risk for certain kinds of fungal infections, such as histoplasmosis. These infections may develop or become more severe if you take ENBREL. If you don't know if these infections are common in the areas you've been to, ask your doctor
  • Have or have had hepatitis B
  • Have or have had heart failure
  • Develop symptoms such as persistent fever, bruising, bleeding, or paleness while taking ENBREL
  • Use the medicine Kineret® (anakinra), Orencia® (abatacept), or Cytoxan® (cyclophosphamide)
  • Are taking anti-diabetic medicines
  • Have, have had, or develop a serious nervous disorder, seizures, any numbness or tingling, or a disease that affects your nervous system such as multiple sclerosis or Guillain-Barré syndrome
  • Are scheduled to have surgery
  • Have recently received or are scheduled for any vaccines. All vaccines should be brought up-to-date before starting ENBREL. Patients taking ENBREL should not receive live vaccines.
  • Are allergic to rubber or latex
  • Are pregnant, planning to become pregnant, or breastfeeding
  • Have been around someone with chicken pox

What are the possible side effects of ENBREL?

ENBREL can cause serious side effects including: New infections or worsening of infections you already have; hepatitis B can become active if you already have had it; nervous system problems, such as multiple sclerosis, seizures, or inflammation of the nerves of the eyes; blood problems (some fatal); new or worsening heart failure; new or worsening psoriasis; allergic reactions; autoimmune reactions, including a lupus-like syndrome and autoimmune hepatitis.

Common side effects include: Injection site reactions, upper respiratory infections (sinus infections), and headache.

In a medical study of patients with JIA, infection, headache, abdominal pain, vomiting, and nausea occurred more frequently than in adults. The kinds of infections reported were generally mild and similar to those usually seen in children. Other serious adverse reactions were reported, including serious infection and depression/personality disorder.

These are not all the side effects with ENBREL. Tell your doctor about any side effect that bothers you or does not go away.

If you have any questions about this information, be sure to discuss them with your doctor. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see Prescribing Information and Medication Guide.

INDICATIONS

Moderate to Severe Rheumatoid Arthritis (RA)

ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse, and improving physical function in patients with moderate to severe rheumatoid arthritis. ENBREL can be taken with methotrexate or used alone.

Moderately to Severely Active Polyarticular Juvenile Idiopathic Arthritis (JIA)

ENBREL is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in children ages 2 years and older.

Psoriatic Arthritis

ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse, and improving physical function in patients with psoriatic arthritis. ENBREL can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone.

Ankylosing Spondylitis (AS)

ENBREL is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.

Adult Chronic Moderate to Severe Plaque Psoriasis

ENBREL is indicated for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.


Supportive Data
Moderate to Severe Rheumatoid Arthritis (RA)
In medical studies, ENBREL was shown to be clinically effective in about 2 out of 3 adults with moderate to severe RA at 3 months. ENBREL has been shown to begin working in as few as 2 weeks, and most patients who benefit will do so within 3 months. In one medical study, among those patients who could be evaluated 5 years after ENBREL therapy, 55% had no further progression of joint damage.